Abstract:Objective: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy. Data sources: This review was based on a comprehensive search using online literature databases, including PubMed, Web of Science, and Google Scholar. Study selection: Literature search was based on the following keywords: Alzheimer's disease, tau protein, biomarker, cerebrospinal fluid (CSF), therapeutics, plasma, imaging, propagation, spreading, seeding, prion, conformational templating, and posttranslational modification. Relevant articles were carefully reviewed, with no exclusions applied to study design and publication type. Results: Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD. Although the Aβ hypothesis has dominated AD research for many years, clinical Aβ-targeting strategies have consistently failed to effectively treat AD or prevent AD onset. The research focus in AD has recently shifted to the role of tau in AD. In addition to phosphorylation, tau is acetylated and proteolytically cleaved, which also contribute to its physiological and pathological functions. Emerging evidence characterizing pathological tau propagation and spreading provides new avenues for research into the molecular and cellular mechanisms underlying AD pathogenesis. Techniques to detect tau at minute levels in CSF and blood have been developed, and improved tracers have facilitated tau imaging in the brain. These advances have potential to accurately determine tau levels at early diagnostic stages in AD. Given that tau is a potential therapeutic target, anti-tau immunotherapy may potentially be a viable treatment strategy in AD intervention. Conclusion: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.

Research Progress on Lncrnas in Alzheimer's Disease.

Insights into Lncrnas in Alzheimer's Disease Mechanisms.

Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

New Insights into lncRNAs in Aβ Cascade Hypothesis of Alzheimer's Disease

The Association between Long Non-Coding RNAs and Alzheimer's Disease

Long Non-Coding RNAs with Essential Roles in Neurodegenerative Disorders

Exploring the Frontier: Antisense Long Non-Coding RNAs As Key Regulators in Alzheimer's Disease.

The Role of Non-coding RNAs in Alzheimer’s Disease: From Regulated Mechanism to Therapeutic Targets and Diagnostic Biomarkers

Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer's Disease

Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimer's disease

Elucidating the Functional Roles of Long Non-Coding RNAs in Alzheimer's Disease

Role of long non-coding RNAs in the pathophysiology of Alzheimer's disease and other dementias

Non-coding RNAs involved in the molecular pathology of Alzheimer's disease: a systematic review

Long Non-coding RNAs in Pathogenesis of Neurodegenerative Diseases

Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases

Identification of Key Long Non-Coding RNAs in the Pathology of Alzheimer’s Disease and Their Functions Based on Genome-Wide Associations Study, Microarray, and RNA-seq Data

The Role of Non-coding RNAs in Alzheimer's Disease: Pathogenesis, Novel Biomarkers, and Potential Therapeutic Targets.

Transcriptional Regulation of Lncrna Genes by Histone Modification in Alzheimer’s Disease

Noncoding RNAs in Alzheimer’s Disease: Overview of Functional and Therapeutic Significance

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease